Marker Therapeutics (MRKR) Operating Leases (2019 - 2023)

Marker Therapeutics (MRKR) has 5 years of Operating Leases data on file, last reported at $6.8 million in Q1 2023.

• Operating Leases for Q1 2023 came in at $6.8 million, down 41.68% year-over-year; the trailing twelve-month figure through Mar 2023 was $6.8 million (down 41.68% YoY), and the FY2022 annual result was $7.0 million, down 37.42% from the prior year.
• Operating Leases retreated to $6.8 million in Q1 2023 per MRKR's latest filing, from $7.0 million in the prior quarter.
• Over five years, Operating Leases peaked at $12.2 million in Q1 2021 and troughed at $280247.0 in Q4 2019.
• A 5-year average of $7.4 million and a median of $9.5 million in 2020 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2020 and 2023: Operating Leases soared 4134.99% in 2020, then tumbled 41.68% in 2023.
• A 5-year view of Operating Leases shows it stood at $280247.0 in 2019, then soared by 4134.99% to $11.9 million in 2020, then declined by 5.23% to $11.2 million in 2021, then plunged by 37.42% to $7.0 million in 2022, then decreased by 3.06% to $6.8 million in 2023.
• Business Quant data shows MRKR's Operating Leases at $6.8 million in Q1 2023, $7.0 million in Q4 2022, and $7.2 million in Q3 2022.